ClinicalTrials.gg
WithdrawnNCT03749096Updated Jun 13, 2019

Randomized Placebo Controlled Trial of IVIg in Glycine Receptor Antibody Positive Stiff-person Syndrome

A Phase 3 interventional study of Intravenous Immunoglobulins, Human and Placebos in Stiff-Person Syndrome, sponsored by Mayo Clinic. Withdrawn at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-06-13.

Sponsored by Mayo Clinic · Phase 3, Interventional, and Treatment

How we know

Why this study was withdrawn
Recruitment did not meet sponsors timeline

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Stiff-Person Syndrome with a site in United States — 4 open to participants now, 5 under way, 1 of them phase 3. Stiff-Person Syndrome · United States.

Enrollment
10th of 10
0 · median 24
Started
2018
the only one that year
Phase 3
Only one
of the 12
Registered
6th of 12
by date
Lead sponsor
1 of 12
Mayo Clinic

Among the 12 studies in Stiff-Person Syndrome with a site in United States, this one is the 10th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2018, is the only one in phase 3, and was the 6th registered.

Stiff-Person Syndrome

20 studies on the registry are indexed under Stiff-Person Syndrome; 8 are open to participants now.

Browse Stiff-Person Syndrome studies →

Open to participants now

4 of the 12 studies in Stiff-Person Syndrome with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 3 Stiff-Person Syndrome studies recruiting now, 2 set no upper age limit and none stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Stiff-Person Syndrome with a site in United States, or all of them as a file.
02

Study summary

This is a randomized double-blind controlled trial of intravenous immunoglobulin (IVIg) for glycine receptor antibody positive (GlyRα1) antibody Stiff Person Syndrome (SPS) spectrum disorders. Adult patients will be enrolled over the course of 36 months. Study duration per patient will be 11 weeks. Total study duration will be 39 months. All treatment and study visits will occur at Mayo Clinic in Rochester, MN.

Read the detailed description

The purpose of this study is to determine whether intravenous immunoglobulin (IVIG) treatment reduces stiffness and spasms in patients with SPS spectrum disorders compared to patients who do not receive any treatment. In this study, investigators want to compare the effects, good and/or bad, of IVIG with placebo on participants with SPS to find out which is better. This is a "randomized, double-blind" study. Which treatment participants will receive is randomly determined. Participants have an equal chance of receiving IVIG or the placebo.

SPS spectrum cohort will include any from the SPS spectrum patient (stiff-limbs, stiff-trunk, stiff-limbs and trunk, and PERM). Study visits will be considered part of clinical care and will occur at: enrollment (will coincide with screening visit), and 11 weeks. IVIg/placebo (saline) treatments will be administered on 2 consecutive days in week 1, week 5, week 9 in all patients.

03

Conditions studied

  • Stiff-Person Syndrome

Browse trials for

Keywords

  • IVIG
  • stiff-person syndrome
  • SPS
  • glycine receptor antibody
  • intravenous immunoglobulin
  • GlyRα1
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient must be 18 years of age or older
  • Must have symptoms of SPS for less than 3 years
  • If taking , the patients must be on a stabile dose for 30 days prior to enrolment
  • Patients will have a diagnosis of SPS spectrum disorder based on both of clinical and serological status

Exclusion criteria

Exclusion Criteria

  • Patients on immune suppressants initiated/dose increased in the prior 6 months
  • History of thrombotic episodes within the 2 years prior to enrollment
  • Known allergic or other severe reactions to blood products including intolerability to previous IVIG
  • Previous adequate trial of IVIG as determined by the Principal Investigator
  • IgA deficiency
  • Reproductive status:

    • Women who are pregnant, breastfeeding
    • Women and men of who are unwilling or unable to use an acceptable method of to avoid pregnancy for the entire study period, as evaluated by the investigator.
  • Any surgical procedure within 4 weeks prior to baseline.
  • Evidence of serious uncontrolled concomitant diseases that may preclude patient participation; Other nervous system disease, cardiovascular disease, hematologic/hematopoiesis disease, respiratory disease, muscular disease, endocrine disease, renal/urologic disease, digestive system disease, congenital or acquired severe immunodeficiency
  • Known active infection within 4 weeks prior to baseline.
  • Evidence of chronic active or C.
  • Active ischemic heart disease in the past year prior to baseline.
  • Patients should not have severe renal or hepatic disease
  • Severe hypertension
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Active comparator
    Intravenous immunoglobulin

    IVIg dose will be 2g/kg ideal body weight every 4 weeks (in 2 divided doses on consecutive days) for 12 weeks (3 cycles total).

    Drug: Intravenous Immunoglobulins, Human

  • Placebo comparator
    Placebo

    Drug: Placebos

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Distribution-of-stiffness index

    Scores on this index range from 0 to 6 and reflect the extent of stiffness. with One point being given for stiffness in each of the following areas: lower trunk, upper trunk, legs, arms, face, and abdomen. Lower scores indicate less stiffness.

    Time frame: Screen, Week 11

  2. Change in Heightened-sensitivity scale

    Scores range from 1 to 7 based on response; one point being given for each source of or type of spasm, as follows: unexpected noises, visual stimuli, somatosensory stimuli, voluntary activities, emotional upset or stress, no specific stimuli, and nocturnal spasms. Lower scores indicate less frequent spasms.

    Time frame: Screen, Week 11

07

Study locations

1 site
  • Mayo Clinic in Rochester
    Rochester, Minnesota 55905, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2018 to primary completion in Apr 2019, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2018
First posted
Nov 21, 2018
StartActual
Dec 7, 2018
Primary completionActual
Apr 26, 2019
CompletionActual
Apr 26, 2019
Last update
Jun 13, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03749096
Lead sponsor
Mayo Clinic
Responsible party
Andrew McKeon (Prinicple Investigator, Mayo Clinic) — Principal investigator
First posted
Nov 21, 2018
Start date
Dec 7, 2018
Primary completion
Apr 26, 2019
Completion
Apr 26, 2019
Last update
Jun 13, 2019

Study contacts

Andrew McKeon, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins, Intravenous

Start the discussion